Dr. Otterson on the Utility of Immunotherapy in NSCLC
Gregory A. Otterson, MD, discusses data examining immunotherapy alone versus in combination in non–small cell lung cancer.
Dr. Otterson on When to Start Immunotherapy in NSCLC
Gregory A. Otterson, MD, discusses when to start treatment with immunotherapy in patients with non–small cell lung cancer.
Dr. Otterson on Targetable Biomarkers in Lung Cancer
Gregory A. Otterson, MD, discusses targetable biomarkers in non–small cell lung cancer.
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
2 Clarke Drive Cranbury, NJ 08512